Dendreon & Deceit: Jim Cramer, Pequot Capital -07/19/09 at 12:02 PM CDTby Mark Mitchell

“SELL! SELL! SELL!” shouted Jim Cramer on March 28, 2007. The CNBC “journalist” assured his viewers that the FDA advisory panel would vote that Dendreon’s treatment for prostate cancer was neither safe nor effective (notwithstanding the fact that the FDA had given the treatment “priority review” status because Pro...

Profiting From Demise: Steve Cohen, Millennium Management, and Dendreon -07/09/09 at 11:55 AM CDTby Mark Mitchell

D.H. Blair, the Mafia-affiliated brokerage founded by Lindsay Rosenwald’s father-in-law (the so-called “king of stock fraud”) and managed for some time by Rosenwald and Michael Milken’s former national sales manager, received much of its finance from the family of a man named Zev Wolfson. Mr. Wolfson was also closely involved with...

Bernie Madoff, D.H. Blair, Michael Milken, and the Story of Dendreon ... -07/06/09 at 7:36 PM CDTby Mark Mitchell

The first of the seven “colorful” hedge funds that held Dendreon put options (right when Provenge was on the fast track to FDA approval) was Bernard L. Madoff Investment Securities, managed by the Mafia-connected criminal who orchestrated a $50 billion Ponzi scheme while helping the SEC write a naked short selling loophole that came to be know...

The Madoff Exemption and the Story of Dendreon (Chapter 2) -06/30/09 at 5:32 PM CDTby Mark Mitchell

In January 2007, some 15 months after CNBC’s Jim Cramer announced that the FDA had rejected Provenge (even though the agency had not yet reviewed Provenge), the FDA assigned “priority review status” to Dendreon’s application to have the drug approved. Such status is typically granted to drugs whose trials suggest that they can sign...